To investigate the influence of

153

Sm-EDTMP and

89

SrCl

2

on immune function in patients with multiple bone metastate. 86 cases of multiple bone metastases were treated with

153

Sm-EDTMP and

89

SrCl

2

during the period of 1995-1998. The patient’s RBC

WBC

T lymphocyte subset

blood immunoglobulin and tumor necrosis factor（TNF） were also measured. Difference in the RBC

T lymphocyte subset

and immunoglobulin and TNF before and after therapy and also between

153

Sm-EDTMP and

89

SrCl

2

group both was not significant （P

>

0.05）. Althrough the WBC have decreased

but still within normal range. As the dose of

153

Sm-EDTMP increased

the toxicity of bone narrow rose then the WBC and RBC of patient and blood IgG decreased

however

T lymphocyte subset has not changed. Common dosage of

153

sm-EDTMP and

89

SrCl

2

did not influence patient’s immune function significantly. However with the increasing of therapeutic dose it’s inevitable to influence their immune function and possible to effect the humonal function first.